Psychotropic prescribing in UK primary care during the COVID-19 pandemic: national interrupted time-series analysis
BJPsych Open · 2026-07 · 12 (4)
DOI: 10.1192/bjo.2026.12054 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJPsych Open, online erschienen am 28.07.2026. Verfasst von Amanj Kurdi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The COVID-19 pandemic disrupted healthcare delivery and coincided with increased psychological distress worldwide. In the UK, restrictions on healthcare access, rapid adoption of remote consultations and pressures on mental health services may have influenced prescribing of psychotropic medications. However, evidence comparing prescribing trends across the four UK nations during the pandemic remains limited.
Aims
To examine trends in community prescribing of psychotropic medicines across England, Scotland, Wales and Northern Ireland before and during the COVID-19 pandemic.
Method
We conducted a repeated cross-sectional study of national Prescription Cost Analysis data-sets covering March 2019 to March 2023. Monthly utilisation of antidepressants, anxiolytics/hypnotics, antipsychotics and antidementia medicines was measured, using two indicators: number of items dispensed per 1000 inhabitants and defined daily doses per 1000 inhabitants per day. Interrupted time-series regression was applied to assess changes in prescribing levels and trends associated with the first (March 2020) and second (November 2020) UK national lockdowns.
Results
Psychotropic prescribing increased across most medicine classes during the study period. Antidepressant utilisation increased by 24.6% across the UK, representing the largest rise among psychotropic medicines. Antipsychotic prescribing increased by 2.7%; anxiolytic/hypnotic prescribing showed modest overall change (2.7%), but this varied between nations, increasing in Scotland (7.3%) and Northern Ireland (7.4%), and declining in Wales (−9.5%). Antidementia medicines increased modestly overall (9.3%), with variation between countries. Interrupted time-series analyses indicated that most changes occurred gradually rather than abrupt shifts following lockdowns.
Conclusions
Psychotropic prescribing increased during the COVID-19 period, but largely reflected continuation of pre-existing trends rather than immediate effects of lockdown restrictions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
- College of Pharmacy, Al-Kitab University, Kirkuk, Iraq.
- Department of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa.
- College of Pharmacy, Hawler Medical University, Erbil, Iraq.
- Department of Engineering, College of Engineering and Technology, University of Technology and Applied Sciences, Muscat, Oman.
- Primary Care, NHS Greater Glasgow and Clyde, Glasgow, UK.
ORCID-Profile: Amanj Kurdi
Zitieren
APA
Kurdi, A., Alrahmani, A., Bakar, S., Johnson, C., & Godman, B. (2026). Psychotropic prescribing in UK primary care during the COVID-19 pandemic: national interrupted time-series analysis. BJPsych Open, 12(4). https://doi.org/10.1192/bjo.2026.12054
Vancouver
Kurdi A, Alrahmani A, Bakar S, Johnson C, Godman B. Psychotropic prescribing in UK primary care during the COVID-19 pandemic: national interrupted time-series analysis. BJPsych Open. 2026;12(4). doi:10.1192/bjo.2026.12054
BibTeX
@article{Kurdi2026,
author = {Kurdi, Amanj and Alrahmani, Abdullah and Bakar, Saher and Johnson, Chris and Godman, Brian},
title = {Psychotropic prescribing in UK primary care during the COVID-19 pandemic: national interrupted time-series analysis},
journal = {BJPsych Open},
year = {2026},
volume = {12},
number = {4},
doi = {10.1192/bjo.2026.12054}
}
EUVIMED